Press Releases

MGEN $1.13 $ - 0.10 (8.13%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
8/15/2019
8:00 AM ET
Press Release

miRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare Conference

8/15/2019

BOULDER, Colo., Aug. 15, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...

 Continue Reading
8/12/2019
8:00 AM ET
Press Release

miRagen Therapeutics to Present a Corporate Overview at the 2019 Wedbush Healthcare Conference

8/12/2019

BOULDER, Colo., Aug. 12, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...

 Continue Reading
8/7/2019
4:05 PM ET
Earnings Release

miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring

8/7/2019

miRagen to regain global rights to MRG-110 after Servier provides notice of portfolio realignment; expects to announce Phase 1 data during the second half of 2019Company anticipates reporting primary...

 Continue Reading
7/24/2019
8:00 AM ET
Press Release

Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7th

7/24/2019

BOULDER, Colo., July 24, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...

 Continue Reading
5/28/2019
4:30 PM ET
Press Release

miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference

5/28/2019

BOULDER, Colo., May 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific f...

 Continue Reading
Displaying 1 to 5 (of 82 releases)